Soluble fiber fermentation by gut bacteria produces short-chain fatty acids, particularly butyrate, that directly stimulate GLP-1 secretion
Discontinuation rates and dose escalation strategies Treatment discontinuation occurred in 7% of semaglutide recipients versus 5% with placebo
Bydureon kept exenatide relevant as newer GLP-1 drugs emerged, but eventually exenatides role diminished since newer agents offered even greater efficacy
Wegovy prescribing information lists headache among adverse reactions occurring in at least 5 percent of adults
When your doctor understands the prescription and over-the-counter medications you use, it is easier for them to check for drug interactions
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist widely explored in laboratory and experimental research settings related to metabolic regulation, glucose-homeostasis pathways, appetite-related signaling, and adipose-related research models